XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Collaboration Agreements, License Agreement and Revenues - Summary of Revenue Recognized Under the Collaboration Agreements - Additional Information 4 (Detail)
 6 Months Ended
Jun. 30, 2024
USD ($)
Europe [Member] | Astellas Agreement [Member]  
Disaggregation of Revenue [Line Items]  
Changes in revenue from changes to estimated variable consideration $ 0
Total Consideration 906,297,000
Europe [Member] | Astellas Agreement [Member] | License [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 618,975,000
U.S./RoW and China [Member]  
Disaggregation of Revenue [Line Items]  
Changes in revenue from changes to estimated variable consideration 0
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | License [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 344,500,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | Co Development Information Sharing And Committee Services [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 625,500,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | China Performance Obligation [Member]  
Disaggregation of Revenue [Line Items]  
Total Consideration 427,500,000
U.S./RoW and China [Member] | AstraZeneca Agreements [Member] | Product [Member]  
Disaggregation of Revenue [Line Items]  
Cumulative Revenue $ 268,900,000